

10. (amended) The method of claim 1, wherein said composition is administered systemically.

11. (amended) A method of ^{to inhibit?} preventing development of atherosclerosis in a subject, comprising administering to said subject a composition comprising cystatin C.

12. (amended) The method of claim 11, wherein said subject is at risk of developing atherosclerosis.

B³ 13. (amended) A method of treating atherosclerosis in a subject, comprising administering to said subject a composition comprising transforming growth factor beta 1.

14 (twice amended) A method of ^u preventing development ^u of atherosclerosis in a subject, comprising administering to said subject a composition comprising transforming growth factor beta 1.

R126 22
15. (new) A method of treating or preventing atherosclerosis in a subject, comprising administering to said subject a composition comprising a polypeptide of SEQ ID NO:3.

B⁴ 23
16. (new) A method of treating or preventing atherosclerosis, comprising identifying a subject suffering from or at risk of developing an atherosclerosis disease and administering to said subject a composition comprising cystatin C.

REMARKS

14-22-23
Upon entry of this amendment, claims 1, 9-16 are pending in the instant application. Claims 15 and 16 are new. The present amendments are fully supported by the specification. No new matter has been added.

1. Objection to the Information Disclosure Statement